Ianalumab Biosimilar Monoclonal Antibody (BAFF-R) for Research

Cat No.: GMP-Bios-ab-256

Pre-Made Ianalumab biosimilar, Whole mAb, Anti-TNFRSF13C Antibody: Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ianalumab (INN; development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-256-1mg 1mg 618

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Ianalumab biosimilar, Whole mAb, Anti-TNFRSF13C Antibody: Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin therapeutic antibody
INN Name Ianalumab
TargetTNFRSF13C
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesH. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis
Conditions Approvedna
Conditions ActiveAutoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia
Conditions Discontinuedna
Development TechPOTELLIGENT Technology



About target - TNFRSF13C

1. Protein Tumor necrosis factor receptor superfamily member 13C

2. Gene TNFRSF13C

3. Organism Homo sapiens (Human)

Function
B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.